134 related articles for article (PubMed ID: 11565837)
1. Effects of isolated limb perfusion with tumor necrosis factor-alpha on circulating levels of proinflammatory cytokines.
Ferroni P; Di Filippo F; Martini F; Spila A; D'Alessandro T; Cavaliere F; Anzà M; Garinei R; Aloe S; Carone MD; Gazzaniga PP; Guadagni F
J Immunother; 2001; 24(4):354-62. PubMed ID: 11565837
[TBL] [Abstract][Full Text] [Related]
2. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage.
Stam TC; Swaak AJ; de Vries MR; ten Hagen TL; Eggermont AM
Ann Surg Oncol; 2000 May; 7(4):268-75. PubMed ID: 10819366
[TBL] [Abstract][Full Text] [Related]
3. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
[TBL] [Abstract][Full Text] [Related]
4. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
[TBL] [Abstract][Full Text] [Related]
5. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
[TBL] [Abstract][Full Text] [Related]
6. [Procalcitonin as marker of systemic inflammatory reaction after isolated extremity perfusion].
Kettelhack C; Hohenberger P; Furchtbar S; Schulze G; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):399-402. PubMed ID: 14518284
[TBL] [Abstract][Full Text] [Related]
7. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Vrouenraets BC; Kroon BB; Ogilvie AC; van Geel AN; Nieweg OE; Swaak AJ; Eggermont AM
Ann Surg Oncol; 1999 Jun; 6(4):405-12. PubMed ID: 10379864
[TBL] [Abstract][Full Text] [Related]
8. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.
Gérain J; Liénard D; Pampallona S; Baumgartner M; Rüegg C; Buurman WA; Eggermont A; Lejeune F
Cytokine; 1997 Dec; 9(12):1034-42. PubMed ID: 9417816
[TBL] [Abstract][Full Text] [Related]
9. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
10. Transient induction of E-selectin expression following TNF alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific.
Nooijen PT; Eggermont AM; Verbeek MM; Schalkwijk L; Buurman WA; de Waal RM; Ruiter DJ
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):33-44. PubMed ID: 8859722
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
12. Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA.
Casara D; Rubello D; Pilati P; Scalerta R; Foletto M; Rossi CR
Nucl Med Commun; 2004 Jan; 25(1):61-6. PubMed ID: 15061266
[TBL] [Abstract][Full Text] [Related]
13. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Hohenberger P; Latz E; Kettelhack C; Rezaei AH; Schumann R; Schlag PM
Ann Surg Oncol; 2003 Jun; 10(5):562-8. PubMed ID: 12794024
[TBL] [Abstract][Full Text] [Related]
14. [Assessment of regional and systemic toxicity of isolated hyperthermic extremity perfusion with tumor necrosis factor-alpha and melphalan].
Hohenberger P; Haier J; Kettelhack C; Schulze G; Schlag PM
Chirurg; 1997 Sep; 68(9):914-20. PubMed ID: 9410682
[TBL] [Abstract][Full Text] [Related]
15. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
Sorkin P; Abu-Abid S; Lev D; Gutman M; Aderka D; Halpern P; Setton A; Kudlik N; Bar-On J; Rudich V
Arch Surg; 1995 Oct; 130(10):1079-84. PubMed ID: 7575120
[TBL] [Abstract][Full Text] [Related]
16. Alterations of circulating bone marrow-derived VEGFR-2+ progenitor cells in isolated limb perfusion with or without rhTNF-α.
Nowak K; Jachol N; Rafat N; Joas E; Beck GCh; Hohenberger P
Ann Surg Oncol; 2013 Oct; 20(11):3694-701. PubMed ID: 22948772
[TBL] [Abstract][Full Text] [Related]
17. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.
van Horssen R; Rens JA; Brunstein F; Guns V; van Gils M; Hagen TL; Eggermont AM
Int J Cancer; 2006 Sep; 119(6):1481-90. PubMed ID: 16615114
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response.
Christoforidis D; Chassot PG; Mosimann F; Lienard D; Brunstein F; Bejko D; Lejeune FJ; Chiolero R
Arch Surg; 2003 Jan; 138(1):17-25. PubMed ID: 12511144
[TBL] [Abstract][Full Text] [Related]
19. High serum levels of TNF-alpha after its administration for isolation perfusion of the limb.
Gérain J; Liénard D; Ewalenko P; Lejeune FJ
Cytokine; 1992 Nov; 4(6):585-91. PubMed ID: 1292642
[TBL] [Abstract][Full Text] [Related]
20. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
